AI platform for biopharma
SOC 2® Type 2
SOC 2® Type 2
Search, evaluate, and prioritize promising therapeutics
VibeOne is the AI platform for biopharma BD, R&D and strategy teams, enabling faster, evidence-based decisions you can defend.
Your proprietary information is never exposed or used to train AI models
The problem
Today’s BD process is slow, fragmented and hard to scale.
Problem 01
It's slow
Each analysis, landscape or diligence takes weeks or months of manual work. The answer can be out of date before a decision is made.
Problem 02
It's fragmented
Data is spread across databases, languages and VDRs. Teams check many sources and risk missing insights.
Problem 03
It doesn't scale
Each review depends on scarce, costly experts and consultants. Lean BD teams are asked to do more with the team they have.
Problem 04
General AI isn't enough
Conventional LLMs miss relevant information, hallucinate and exploit your proprietary data.
Why VibeOne
Answer BD questions faster, bring all your data together and scale with the team you already have.
Answers in minutes, not months
Each BD question is answered in minutes, and the analysis can be re-run whenever priorities shift.
Insights from each function, in one place
Glean insights across key disciplines, from biology to clinical development, sourced from databases, VDRs and 40+ languages. Every finding links to its source.
Scale without extra resources
Evaluate all opportunities across therapeutic areas quickly, using your own customized criteria. Reduce delays and dependence on consultants or experts at scale.
VibeOne results
18x
Faster indication analysis for a pharma client: 10 days vs. 6 months
50%+
More assets found in global landscapes, across 40+ languages
75%
Less expert time needed to reach a trusted due diligence result
4.6×
More assets found in a competitive landscape than a general AI tool
This was a game changer. VibeOne got done in 10 days, what would have taken 6 months. Now we are building drug programs in disease areas that we had never heard of until we used VibeOne.
The outcome
Two new drug programs started in diseases VibeOne surfaced, and the collaboration is expanding.
Who said it
Smitha Jagdish, PhD, VP, Rare Disease and New Modalities, Bial

Five connected products
Every BD effort starts with five questions. Each VibeOne product answers one.
VibeOne
The platform
Indication Prioritization
Strategy you can trustWhat indications do we explore? Rank 20,000+ indications in minutes.
Landscape Analysis
Coverage you can trustWhat assets are in development? Where are the gaps? See one global list, sourced from 40+ geographies.
Asset Triage
Criteria you can trustWhich assets do we focus on? Prioritize every asset, inbound or sourced, against your strategic criteria.
Due Diligence
Evidence you can trustWhat are the risks with this asset? Should we pursue this program? Diligence assets 8x faster, including from VDRs and non-confidential materials.
Commercial Assessment
A model you can trustWhat is it worth? Model revenue and NPV in minutes.
Built for your role
See what VibeOne does for you
Compared
VibeOne against the alternatives
Scale without sacrificing rigor.
VibeOne
Global, consistent, source-traceable analysis at AI scale
Manual
Customized, but slow and unscalable
Consulting
Expensive, with limited context switching
General AI
Easy, but unreliable
One system
VibeOne
Every asset, same criteria, cited to source.
- Time to a first call
- Minutes (Holds up)
- Source checking
- Every claim, to source (Holds up)
- Coverage
- Everything, 40+ languages (Holds up)
- Comparability
- Same standards every time (Holds up)
- Missing data
- Flagged as unknown (Holds up)
- Scaling
- Unlimited assets (Holds up)
One system. One record. One standard.
In-house
Manual process
Bounded by the hours your team has.
- Time to a first call
- 6–10 weeks (Does not)
- Source checking
- Analyst notes (Partial)
- Coverage
- Known players only (Does not)
- Comparability
- Depends who ran it (Does not)
- Missing data
- Often unstated (Partial)
- Scaling
- More headcount (Does not)
Every new asset costs another analyst week.
Outsourced
External consulting
Answers the question you already knew to ask.
- Time to a first call
- 8–12 weeks (Does not)
- Source checking
- Appendix only (Partial)
- Coverage
- Only what you scoped (Partial)
- Comparability
- One-off each time (Does not)
- Missing data
- Often unstated (Partial)
- Scaling
- Per engagement (Does not)
The learning leaves when the engagement ends.
Generic tooling
General AI search
Fast, and impossible to defend.
- Time to a first call
- Minutes (Holds up)
- Source checking
- None you can verify (Does not)
- Coverage
- Whatever is indexed (Partial)
- Comparability
- None (Does not)
- Missing data
- Guessed at (Does not)
- Scaling
- Seat licence (Partial)
Nothing here survives an investment committee.
- Holds up
- Partial
- Does not
Trust & security
Enterprise-grade security, independently examined under SOC 2® Type 2
Latest thinking
View all resources
Scientific insights









